Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 1997

View Archived Issues

Naratriptan highlighted at headache congress; introduced in U.K.

Novel melatonergic agents described by Bristol-Myers Squibb

Encouraging data reported for Sugen's insulin phosphatase inhibitors

Kyowa Hakko claims compounds for thrombocytopenia

FDA advisory committee withholds recommendation of Ilex Oncology's treatment for AIDS-related NHL

Ono describes elastase inhibitors

P&U prepares inhibitors of kynurenine 3-hydroxylase for neurodegenerative diseases

U.S. patents issued to Yale University and Innovir for EGS technology

Selective dopamine D3 receptor ligands from Novo Nordisk

MS&D prepares potent and selective 5-HT1D agonists

Neurogen and Tularik sign drug discovery agreement

Protein farnesyltransferase inhibitors from Janssen

Megabios issued patent for aerosol gene delivery system

Efficacy of SB-206284A in animal models of cerebral ischemia

Positive efficacy profile for MacroChem's erectile dysfunction therapy

Univ. of Tokyo scientists isolate potent and selective papain inhibitor

Abbott selects new motilide as candidate for GI motility disorders

Potential new antidiabetic and antiobesity agent from Dainippon

Case report of congenital abnormalities associated with maternal methotrexate ingestion

Valaciclovir vs. placebo for recurrent genital HSV

NMDA antagonists improve memory deficits after brain injury in the rat

Hypolipidemic effects of F-1394 in hyperlipidemic dogs

Antipruritogenic effect of Kochia Fructus extract and active components

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...